Objective: To observe the efficacy of alogliptin in the treatment of type 2 diabetes in the treatment of type 2 diabetes with the combination of metformin and dapagliflozin in the treatment of type 2 diabetes mellitus. Methods: A total of 79 patients with type 2 diabetes, which were diagnosed and treated in our department from September 2018 to March 2019, were randomly divided into 2 groups, 39 patients in the observation group and 40 in the control group. The observation group was treated with dapagliflozin 10 mg on the basis of metformin alone, and the control group was treated with alogliptin 25 mg on the basis of metformin treatment for 12 weeks. The body weight, glycosylated hemoglobin, total cholesterol and low-density lipoprotein were observed before and after treatment. Results: After 24 weeks of treatment, the weight of the observation group was significantly lower than that before treatment (P<0.05), while that of the control group was not significantly lower than that before treatment (P>0.05). The glycosylated hemoglobin of the two groups was lower than that before treatment (P<0.05), but there was no significant difference between the observation group and the control group, and there was no significant difference in total cholesterol and low density lipoprotein between the two groups before and after treatment (P>0.05), but the decrease of low density lipoprotein in the observation group was significantly lower than that in the control group (P<0.05). Conclusion: alogliptin and dapagliflozin both can effectively control blood glucose in patients with type 2 diabetes mellitus who are not effective in the treatment of metformin alone, but dapagliflozin can effectively control body weight, which may benefit obese type 2 diabetes mellitus and type 2 diabetes patients with elevated low-density lipoprotein.